We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluation of the Performance of ACR TI-RADS Also Considering Those Nodules with No Indication of FNAC: A Single-Center Experience.
- Authors
Amendola, Stefano; Wolde Sellasie, Sium; Pedicini, Francesco; Carlini, Massimo; Russo, Giulia; Ossola, Nicola; Leoncini, Andrea; Botti, Flavia; Bonanno, Elena; Trimboli, Pierpaolo; Uccioli, Luigi
- Abstract
Background: Several US risk stratification score systems (RSSs) have been developed to standardize a thyroid nodule risk of malignancy. It is still a matter of debate which RSS is the most reliable. The purpose of this study is to evaluate: (1) the concordance between the American College of Radiology TI-RADS (ACR TI-RADS) and fine needle aspiration cytology (FNAC), (2) the cancer rate in the ACR TI-RADS categories, (3) the characteristics of nodules evaluated by FNAC even if not formally indicated according to ACR TI-RADS ('not indicated FNACs"). Methods: From January 2021 to September 2022, patients attending the Endocrinology Unit of the CTO Hospital of Rome for evaluation of thyroid nodules were included. Results: 830 nodules had negative cytology, belonging to TIR2 and TIR1C. One hundred and thirteen nodules were determined to be suspicious for or consistent with malignancy belonging to TIR3B/TIR4/TIR5. Of this last group, 94% were classified as TR4/TR5 nodules. In total, 87/113 underwent surgery. Among these, 73 had histologically proven cancer, 14 turned out to be benign. "Not indicated FNACs" was 623. Among these, 42 cancers were present. Conclusions: This study confirmed the diagnostic power of ACR TI-RADS. In addition, these data suggest revising the ACR TI-RADS indication to FNAC, especially for TR4.
- Subjects
THYROID cancer; DISEASE risk factors; THYROID nodules
- Publication
Journal of Clinical Medicine, 2023, Vol 12, Issue 2, p398
- ISSN
2077-0383
- Publication type
Article
- DOI
10.3390/jcm12020398